Please select the option that best describes you:
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Does active smoking status influence this decision?
Answer from: at Community Practice
The factors I consider are recurrent exacerbations, symptoms despite triple therapy, and an eosinophil count that is greater than 300.
What is unclear is the decision regarding chronic azithromycin and/or roflumilast versus dupilumab. It looks like roflumilast was not allowed in the study, and appa...
Sign in or Register to read more
Answer from: at Academic Institution
I look at the history of exacerbations despite LABA/LAMA/ICS compliance.